Carlsmed (CARL) EV to EBITDA (2025 - 2026)

Carlsmed's (CARL) quarterly EV to EBITDA came in at 15.34 in Q2 2026, down 13.94% quarter-over-quarter from 13.46 in Q1 2026.

Analysis

Carlsmed (CARL) EV to EBITDA (2025 - 2026) Analysis & Trends

Carlsmed (CARL) has reported EV to EBITDA for 2 consecutive years, with 15.34 the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, EV to EBITDA changed N/A year-over-year to 15.34; the trailing twelve-month figure through Jun 2026 stood at 4.38 (changed N/A YoY), and the FY2025 full-year result was 2.15, changed N/A from the prior year.
EV to EBITDA fell to 15.34 in Q2 2026 per CARL's latest filing, from 13.46 in the prior quarter.
Across five years, EV to EBITDA topped out at 7.07 in Q4 2025 and bottomed at 18.46 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	187.42 Bn	182.47 Bn	7.27 Bn
2	Intuitive Surgical	129.78 Bn	124.69 Bn	1.96 Bn
3	Medtronic	120.53 Bn	112.33 Bn	6.34 Bn
4	Stryker	116.28 Bn	112.80 Bn	4.50 Bn
5	Boston Scientific	69.29 Bn	68.99 Bn	3.85 Bn
6	Edwards Lifesciences	51.83 Bn	47.68 Bn	1.35 Bn
7	Alcon	34.36 Bn	32.91 Bn	1.68 Bn
8	Dexcom	33.17 Bn	31.23 Bn	830.00 Mn
9	Resmed	32.94 Bn	31.47 Bn	861.22 Mn
10	Carlsmed	424.72 Mn	311.42 Mn	14.54 Mn

Historic Data

Download Data